Dan K - Search Results

1

Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome.

Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K, Sakamaki H, Onozawa Y, Hamaguchi H, Nomura T. Ogata K, et al. Among authors: dan k. Br J Haematol. 1996 Apr;93(1):45-52. doi: 10.1046/j.1365-2141.1996.4641003.x. Br J Haematol. 1996. PMID: 8611474

2

Low-dose etoposide: a potential therapy for myelodysplastic syndromes.

Ogata K, Yamada T, Ito T, Gomi S, Tanabe Y, Ohki I, Dan K, Nomura T. Ogata K, et al. Among authors: dan k. Br J Haematol. 1992 Oct;82(2):354-7. doi: 10.1111/j.1365-2141.1992.tb06429.x. Br J Haematol. 1992. PMID: 1419818

3

Cell-mediated cyclic thrombocytopenia treated with azathioprine.

Dan K, Inokuchi K, An E, Nomura T. Dan K, et al. Br J Haematol. 1991 Mar;77(3):365-70. doi: 10.1111/j.1365-2141.1991.tb08585.x. Br J Haematol. 1991. PMID: 2012761

4

Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.

Ogata K, Tamura H, Yokose N, An E, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Clark SC, Nomura T. Ogata K, et al. Among authors: dan k. Br J Haematol. 1995 May;90(1):15-21. doi: 10.1111/j.1365-2141.1995.tb03375.x. Br J Haematol. 1995. PMID: 7786778

5

Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes.

Yokose N, Ogata K, Ito T, An E, Tamura H, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Nomura T. Yokose N, et al. Among authors: dan k. Leuk Res. 1994 Oct;18(10):777-82. doi: 10.1016/0145-2126(94)90060-4. Leuk Res. 1994. PMID: 7934136

6

Defective natural killer (NK) cell-mediated cytotoxicity does not imply clonal involvement of NK cells in myelodysplastic syndromes.

Ogata K, Fujii H, Yokose N, An E, Tamura H, Kamikubo K, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, et al. Ogata K, et al. Among authors: dan k. Br J Haematol. 1994 Jun;87(2):396-8. doi: 10.1111/j.1365-2141.1994.tb04928.x. Br J Haematol. 1994. PMID: 7947284

7

Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes.

Ogata K, Yokose N, Ito T, An E, Tamura H, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Nomura T. Ogata K, et al. Among authors: dan k. Br J Haematol. 1994 Mar;86(3):562-7. doi: 10.1111/j.1365-2141.1994.tb04787.x. Br J Haematol. 1994. PMID: 8043438

8

Megakaryocyte, erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes.

Dan K, An E, Futaki M, Inokuchi K, Gomi S, Yamada T, Ogata K, Tanabe Y, Ohki I, Shinohara T, et al. Dan K, et al. Acta Haematol. 1993;89(3):113-8. doi: 10.1159/000204502. Acta Haematol. 1993. PMID: 8362599

9

Effects of interleukin 2 on myelodysplastic syndromes.

Ogata K, Yokose N, Ito T, An E, Dan K, Nomura T. Ogata K, et al. Among authors: dan k. Leuk Res. 1993 Feb;17(2):137-42. doi: 10.1016/0145-2126(93)90058-s. Leuk Res. 1993. PMID: 8429690

10

Cell cycle modulation by hematopoietic growth factors in myelodysplastic syndromes: analysis by three-color flow cytometry.

Ogata K, An E, Kamikubo K, Tamura H, Yokose N, Dan K, Nomura T. Ogata K, et al. Among authors: dan k. Exp Hematol. 1997 Jan;25(1):8-18. Exp Hematol. 1997. PMID: 8989901

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

507 results

Search Page

Filters